CA2498176C - Medical device amenable to fenestration - Google Patents
Medical device amenable to fenestration Download PDFInfo
- Publication number
- CA2498176C CA2498176C CA002498176A CA2498176A CA2498176C CA 2498176 C CA2498176 C CA 2498176C CA 002498176 A CA002498176 A CA 002498176A CA 2498176 A CA2498176 A CA 2498176A CA 2498176 C CA2498176 C CA 2498176C
- Authority
- CA
- Canada
- Prior art keywords
- medical device
- implantable medical
- framework
- barrier material
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000463 material Substances 0.000 claims abstract description 118
- 230000004888 barrier function Effects 0.000 claims abstract description 53
- 230000002792 vascular Effects 0.000 claims description 20
- -1 polytetrafluoroethylene Polymers 0.000 claims description 8
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 7
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 229920001971 elastomer Polymers 0.000 claims description 3
- 239000000806 elastomer Substances 0.000 claims description 3
- 229920002313 fluoropolymer Polymers 0.000 claims 4
- 239000004811 fluoropolymer Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 abstract description 11
- 238000004891 communication Methods 0.000 abstract description 6
- 238000005192 partition Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 21
- 239000010410 layer Substances 0.000 description 14
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 11
- 210000002254 renal artery Anatomy 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 10
- 208000007474 aortic aneurysm Diseases 0.000 description 9
- 238000002513 implantation Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 229920009441 perflouroethylene propylene Polymers 0.000 description 5
- 210000001147 pulmonary artery Anatomy 0.000 description 5
- 210000001631 vena cava inferior Anatomy 0.000 description 5
- 206010002329 Aneurysm Diseases 0.000 description 4
- 208000002330 Congenital Heart Defects Diseases 0.000 description 4
- 229920000544 Gore-Tex Polymers 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000004873 anchoring Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940127554 medical product Drugs 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 208000007340 tricuspid atresia Diseases 0.000 description 4
- BLTXWCKMNMYXEA-UHFFFAOYSA-N 1,1,2-trifluoro-2-(trifluoromethoxy)ethene Chemical compound FC(F)=C(F)OC(F)(F)F BLTXWCKMNMYXEA-UHFFFAOYSA-N 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 3
- 210000003090 iliac artery Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 3
- 210000002620 vena cava superior Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 201000008982 Thoracic Aortic Aneurysm Diseases 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005831 heart abnormality Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000013152 interventional procedure Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 230000004088 pulmonary circulation Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 238000009958 sewing Methods 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 238000005476 soldering Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- JJTUDXZGHPGLLC-QWWZWVQMSA-N (3r,6r)-3,6-dimethyl-1,4-dioxane-2,5-dione Chemical compound C[C@H]1OC(=O)[C@@H](C)OC1=O JJTUDXZGHPGLLC-QWWZWVQMSA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 229910000619 316 stainless steel Inorganic materials 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000592503 Speea Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010045545 Univentricular heart Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009760 electrical discharge machining Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229920001973 fluoroelastomer Polymers 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 238000001259 photo etching Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000036593 pulmonary vascular resistance Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229920002631 room-temperature vulcanizate silicone Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3478—Endoscopic needles, e.g. for infusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/89—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2002/061—Blood vessels provided with means for allowing access to secondary lumens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2002/065—Y-shaped blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/075—Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/821—Ostial stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/005—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0058—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements soldered or brazed or welded
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0075—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Prostheses (AREA)
- Surgical Instruments (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention is directed to a device that permits a permanent aperture to be formed in a wall, or other partition, of an implantable medical device. The present invention maintains the continuity and fluid-retaining properties of the implantable medical device by providing a breachable barrier material fully covering an opening delimited by a deformable framework. The invention is accessed with conventional interventional surgical instruments that disrupt and displace the barrier material. Following disruption of the barrier material, the opening is enlarged with surgical instruments to form a permanent framed aperture in the wall of the implantable medical device. The permanent framed aperture provides fluid communication across the wall of the implantable medical device.
Description
MEDICAL DEVICE AMENABLE TO FENESTRATION
FIELD OF THE INVENTION
The present invention relates to implantable medical devices. More particularly, the invention relates to means for forming a framed aperture in wall portions, or other partitions, of implantable medical devices to establish and maintain fluid communication across the wall portion of the medical device. The present invention also relates to methods of making the invention.
BACKGROUND OF THE INVENTION
Abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs) are diagnosed in approximately 250,000 and 20,000 patients respectively each year.
Left untreated, these aneurysms commonly progress to rupture resulting in death.
Prior to the advent of interventional catheter-based techniques, conventional surgical treatment has been the method of treatment for these lesions. Due to the often emergent condition of these patients and the potential for significant blood loss, high morbidity and mortality rates have been associated with this type of surgery.
2o With the introduction of catheter-based interventional techniques, new non-surgical therapies were made available to many patients. Since the initial animal work performed by Schatz et. al., small metallic tubes (i.e., stents) have been found to be of significant benefit for patients with coronary artery and peripheral artery disease. Schatz, R.A., Palmaz, J.C., Tio, F.O., Garcia, F., Garcia, O., Reuter, S.R. "Balloon-expandable intracoronary stents in the adult dog." Circulation 76:450-7 (1987). In an effort to treat abdominal aortic aneurysms, Parodi et. al. reported on their experience with combining the barrier properties of synthetic vascular grafts with stent technology (i.e., stent-graft) to effectively inhibit blood flow into the aneurysm sac using catheter delivery systems. Parodi, J.C., Palmaz, J.C., Barone, H.D. "Transfemoral intraluminal graft implantation for abdominal aortic aneurysms."
3o Ann. Vasc. Surg 5:491-9 (1991).
This technology has continued to progress with significant improvements in successful device deployment and improved patient outcomes. Despite these improvements, there are many patients for which this technology is not applicable as a result of unique anatomical or disease conditions. Specifically, in the case of AAA
disease, stent-graft devices typically require some amount of healthy vessel both proximal and distal to the aneurysm sac into which to place the stent-graft. In many patients, the proximal vessel is not long enough to achieve adequate fixation. Placement of the stent-graft in a more proximal location in these patients in order to achieve adequate fixation could partially or completely occlude the renal arteries providing blood to the kidneys. A number of different device designs have been proposed to allow device fixation to the aortic vessel proximal to the renal arteries (i.e., suprarenal fixation). Widespread applicability of supra-renal fixation devices has been limited by the flexibility of these designs, morphological variation of aneurysmal neck geometry across patients, and the coverage of the renal ostia with metallic stents which can act as a nidus for thromo-embolism of the renal circulation and/or hinder subsequent interventional access to this vasculature.
A similar situation exists for TAA disease. These aneurysmal lesions are often to located in close proximity to the subclavian and carotid arterial branches.
When inadequate proximal vascular tissue is available for anchoring the endoprosthesis, a suitable proximal anchoring zone can be created by performing a surgical transposition prior to the interventional procedure. This surgical approach is intended to assure continued flow to all vessels. Alternative means for achieving side-branch perfusion through the wall of a stent-15 graft are therefore desirable.
Other clinical conditions where there would be a benefit for fluid communication through the wall of a prosthesis are those involving cardiac surgery. Arterial blood leaving the heart serves to carry oxygen to the body. In contrast, venous blood is returned to the heart via the superior and inferior vena cava after releasing oxygen to the body and 2o absorbing carbon dioxide and other waste products. Approximately 40,000 children are born each year with congenital heart defects. These abnormalities often involve a single functional ventricle and defects in the tissues (i.e., septum) separating the right (venous) and left (arterial) side of the heart. Mixing of arterial and venous blood in these patients results in reduced oxygen carrying capacity and often shortened life expectancies.
25 Cardiac surgical interventions performed for the most complex congenital heart abnormalities often require multiple surgical procedures to effect the final treatment for the patient. The Fontan procedure is an example of a staged surgical treatment that is designed to overcome these significant structural heart abnormalities and isolate systemic and pulmonary circulation at the definitive treatment. "Correction de I'atresie tricuspidienne."
3o Fontan, F., Mounicot, F.B., Baudet, E., Simonneau, J, Gordo, J., Gouffrant, J.M.. Rapport de deux cas "corriges" par ('utilisation dune technique chirurgicale nouvelle.
["Correction" of tricuspid atresia. 2 cases "corrected" using a new surgical technic] Ann-Chir-Thorac-Cardiovase 10:39-47 (1971). Annecchino, F.P., Fontan, F., Chauve, A., Quaegebeur, J.
"Palliative reconstruction of the right ventricular outflow tract in tricuspid atresia: a report of 5 35 patients." Ann-Thorac-Surg.29:317-21 (1980). Ottenkamp, J., Rohmer, J., Quaegebeur, J.M., Brom, A.G., Fontan, F. "Nine years' experience of physiological correction of tricuspid atresia: long-term results and current surgical approach." Thorax 37:718-26 (1982). The
FIELD OF THE INVENTION
The present invention relates to implantable medical devices. More particularly, the invention relates to means for forming a framed aperture in wall portions, or other partitions, of implantable medical devices to establish and maintain fluid communication across the wall portion of the medical device. The present invention also relates to methods of making the invention.
BACKGROUND OF THE INVENTION
Abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs) are diagnosed in approximately 250,000 and 20,000 patients respectively each year.
Left untreated, these aneurysms commonly progress to rupture resulting in death.
Prior to the advent of interventional catheter-based techniques, conventional surgical treatment has been the method of treatment for these lesions. Due to the often emergent condition of these patients and the potential for significant blood loss, high morbidity and mortality rates have been associated with this type of surgery.
2o With the introduction of catheter-based interventional techniques, new non-surgical therapies were made available to many patients. Since the initial animal work performed by Schatz et. al., small metallic tubes (i.e., stents) have been found to be of significant benefit for patients with coronary artery and peripheral artery disease. Schatz, R.A., Palmaz, J.C., Tio, F.O., Garcia, F., Garcia, O., Reuter, S.R. "Balloon-expandable intracoronary stents in the adult dog." Circulation 76:450-7 (1987). In an effort to treat abdominal aortic aneurysms, Parodi et. al. reported on their experience with combining the barrier properties of synthetic vascular grafts with stent technology (i.e., stent-graft) to effectively inhibit blood flow into the aneurysm sac using catheter delivery systems. Parodi, J.C., Palmaz, J.C., Barone, H.D. "Transfemoral intraluminal graft implantation for abdominal aortic aneurysms."
3o Ann. Vasc. Surg 5:491-9 (1991).
This technology has continued to progress with significant improvements in successful device deployment and improved patient outcomes. Despite these improvements, there are many patients for which this technology is not applicable as a result of unique anatomical or disease conditions. Specifically, in the case of AAA
disease, stent-graft devices typically require some amount of healthy vessel both proximal and distal to the aneurysm sac into which to place the stent-graft. In many patients, the proximal vessel is not long enough to achieve adequate fixation. Placement of the stent-graft in a more proximal location in these patients in order to achieve adequate fixation could partially or completely occlude the renal arteries providing blood to the kidneys. A number of different device designs have been proposed to allow device fixation to the aortic vessel proximal to the renal arteries (i.e., suprarenal fixation). Widespread applicability of supra-renal fixation devices has been limited by the flexibility of these designs, morphological variation of aneurysmal neck geometry across patients, and the coverage of the renal ostia with metallic stents which can act as a nidus for thromo-embolism of the renal circulation and/or hinder subsequent interventional access to this vasculature.
A similar situation exists for TAA disease. These aneurysmal lesions are often to located in close proximity to the subclavian and carotid arterial branches.
When inadequate proximal vascular tissue is available for anchoring the endoprosthesis, a suitable proximal anchoring zone can be created by performing a surgical transposition prior to the interventional procedure. This surgical approach is intended to assure continued flow to all vessels. Alternative means for achieving side-branch perfusion through the wall of a stent-15 graft are therefore desirable.
Other clinical conditions where there would be a benefit for fluid communication through the wall of a prosthesis are those involving cardiac surgery. Arterial blood leaving the heart serves to carry oxygen to the body. In contrast, venous blood is returned to the heart via the superior and inferior vena cava after releasing oxygen to the body and 2o absorbing carbon dioxide and other waste products. Approximately 40,000 children are born each year with congenital heart defects. These abnormalities often involve a single functional ventricle and defects in the tissues (i.e., septum) separating the right (venous) and left (arterial) side of the heart. Mixing of arterial and venous blood in these patients results in reduced oxygen carrying capacity and often shortened life expectancies.
25 Cardiac surgical interventions performed for the most complex congenital heart abnormalities often require multiple surgical procedures to effect the final treatment for the patient. The Fontan procedure is an example of a staged surgical treatment that is designed to overcome these significant structural heart abnormalities and isolate systemic and pulmonary circulation at the definitive treatment. "Correction de I'atresie tricuspidienne."
3o Fontan, F., Mounicot, F.B., Baudet, E., Simonneau, J, Gordo, J., Gouffrant, J.M.. Rapport de deux cas "corriges" par ('utilisation dune technique chirurgicale nouvelle.
["Correction" of tricuspid atresia. 2 cases "corrected" using a new surgical technic] Ann-Chir-Thorac-Cardiovase 10:39-47 (1971). Annecchino, F.P., Fontan, F., Chauve, A., Quaegebeur, J.
"Palliative reconstruction of the right ventricular outflow tract in tricuspid atresia: a report of 5 35 patients." Ann-Thorac-Surg.29:317-21 (1980). Ottenkamp, J., Rohmer, J., Quaegebeur, J.M., Brom, A.G., Fontan, F. "Nine years' experience of physiological correction of tricuspid atresia: long-term results and current surgical approach." Thorax 37:718-26 (1982). The
2 surgical procedures must be staged to minimize the pressure and volume loads on the remaining functional single ventricle. In the first stage procedure, a connection is created between the Superior Vena Cava (SVC) and the Pulmonary Artery (PA). This is referred to as a Hemi-Fontan or Glenn Shunt procedure. Mathur, M., Glenn, W.W. "Rational approach to the surgical management of tricuspid atresia." Circulation 37:1162-7 (1968). This shunt reduces the degree of venous and arterial blood mixing, and improves oxygenation of the blood.
Once the pulmonary circulation and functional ventricle are sufficiently developed, a subsequent procedure is performed wherein the blood going to the right ventricle is to bypassed by routing the blood in the Inferior Vena Cava (IVC) directly to the PA by way of a baffle or tube connecting the IVC to the PA. At the time of this procedure, a small hole is typically created in the side of the connection tube to allow some flow of blood into the right ventricle. This small hole is considered a temporary connection that reduces the work for the remaining ventricle when pulmonary vascular resistance is elevated. Bridges, N.D., Mayer, 15 J.E., Lock, J.E., Jonas, R.A., Hanley, F.L., Keane, J.F., Perry, S.B., Castaneda, A.R. "Effect of baffle fenestration on outcome of the modified Fontan operation."
Circulation 86:1762-9 (1992). ' The final surgical procedure involves either surgical closure or transcatheter occlusion of the temporary hole in the IVC to PA connector tube. This multi-staged 2o conventional surgical approach for patients with complex congenital heart disease is not optimal as it puts patients at additional risk of morbidity and mortality with each subsequent surgical intervention. This risk may be reduced if the first surgical intervention can set the stage for a future minimally invasive procedure that eliminates the need for additional open-heart surgery.
25 Various devices and design modifications have been proposed in an effort to provide access to anatomical structures surrounding the device or to internal spaces of the device.
U.S. Pat. No. 6,428,565, issued to Wisselink, and U.S. Pat. No. 6,395,018, issued to Castaneda, each relate to stent-graft systems with pre-formed apertures to allow for side-branch access. Neither of these devices have apertures that are closed at the time of initial 30 implant.
U.S. Pat. No. 6,398,803, issued to Layne, et. al., relates to partially covered stents having various patterns of open apertures along the length of the device. As with the Wisselink and Castaneda devices, the apertures are fully formed prior to deployment of the device.
35 U.S. Pat. No. 6,432,127, issued to Kim, et. al., discloses formation of an aperture in the wall of a vascular conduit through the use of a cutting tool. The conduit does not provide a deformable framework encompassing the aperture formation site. As a result, targeting the precise location of the region in which to create the aperture is difficult to visualize using conventional imaging techniques. Moreover, the aperture is not reinforced along its peripheral regions once the aperture is formed. The absence of a framework delimiting the aperture formation site precludes precise sizing of the aperture during its formation.
There remains a need for a device that initially maintains the continuity and fluid-retaining properties of a wall portion of an implantable medical device, while providing means for forming a permanent aperture in the medical device. Such a device would permit custom sizing of the aperture in situ at the implant site during surgery.
to SUMMARY OF THE INVENTION
The present invention is directed to a device that is amenable to transmural fenestration. In particular, the present invention permits a permanent framed aperture to be formed in a wall, or similar partition, of implantable medical devices as a means for 15 establishing and maintaining fluid communication across the wall of the medical device following implantation. The present invention provides a breachable barrier material that initially maintains the continuity and any fluid-retaining properties of the wall of the medical device. The breachable barrier material fully covers an opening delimited by a framework.
In use, the breachable barrier material is breached with a surgical instrument and the shape 20 of the framework altered to enlarge, or otherwise alter, the area of the opening. In the process, the opening becomes uncovered and accessible to flow of fluid through the opening. The altered framework provides structural reinforcement to peripheral regions (e.g., circumferential) of the enlarged opening and forms a permanent aperture in the wall of the medical device. The altered framework can also be used to provide a secure anchoring 25 site for ancillary medical devices. The permanent aperture can be formed in the wall of the implantable medical device at the time of surgical or catheter-based intervention or at a later date through the use of interventional or surgical techniques.
The present invention is particularly suited for use with vascular prostheses, and other implantable medical devices providing fluid containment or fluid partitioning, that can 30 benefit from the formation of one or more permanent apertures in the devices at the implantation site. With stent-grafts spanning an aneurysm, for example, the invention can provide a framed aperture in the wall of the stent-graft for side-branches or drainage sites.
Vascular grafts can be bypassed or bifurcated in-situ with the present invention. The invention can also be used with surgically implanted cardiovascular patches to provide 35 perfusion or other access to the heart and vascular system.
The present invention can be added to an implantable medical device following its construction, or included in the manufacture of the device as an integral component. The breachable barrier material of the present invention is made of implantable polymers that are readily breached, perforated, or otherwise structurally disrupted with surgical instruments.
The breachable barrier material can also be made of polymers that are structurally disrupted through degradation and absorption by the body of the implant recipient. The polymers of the breachable barrier material can be incorporated with filler materials to assist in breaching the barrier material or to facilitate visualization of the aperture region in an implant recipient.
The framework is made of implantable metallic or polymeric materials that can be altered in shape. These framework materials can be deformed or otherwise altered in shape with surgical instruments or have shape-memory properties that permit the framework to 1o assume different shapes without the use of an instrument. The framework materials are shaped in various ways to assist in the combined roles of structurally reinforcing the breachable barrier material and the opening, being capable of reconfiguration, and providing a permanent framed aperture.
In one surgical method, an implantable medical device utilizing the present invention 15 is placed at a surgical site with conventional or interventional surgical techniques. Once the correct position of the medical device is confirmed, a catheter guide-wire, or other surgical instrument, is used to breach the breachable barrier material and begin to uncover the covered opening. An expandable balloon catheter in a deflated configuration is then inserted into the partially uncovered opening and inflated. As the balloon catheter is inflated, 2o it expands in diameter, altering the shape of the framework and displacing the remaining barrier material from the area of the opening. When the framework has been reconfigured as desired, the balloon catheter is deflated and removed from the opening.
This leaves a permanent framed aperture in the wall of the medical device. The permanent aperture can provide immediate therapies and surgical remedies, such as branch vessel perfusion, or co-25 operate with other medical devices.
In one embodiment, the present invention is an implantable medical device comprising a framework delimiting an opening having a first area and a breachable barrier material fully covering said opening, wherein a permanent aperture having a second area is formed following breach of said breachable material and said framework is adaptable to be 3o altered in shape.
In another embodiment, the present invention is an implantable medical device comprising a continuous wall, at least one framework in said wall delimiting an opening having a first area, a breachable barrier material fully covering said opening, wherein a permanent aperture having a second area is formed following breach of said breachable 35 material and said framework is adaptable to be altered in shape and have a reinforced peripheral region in said continuous wall.
Further aspects and advantages of the present invention will be apparent to those skilled in the art after reading and understanding the detailed description of preferred embodiments set forth hereinbelow and after viewing the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing summary, as well as the following detailed description of a preferred embodiment of the invention, will be better understood when read in conjunction with the appended drawings. For purposes of illustrating the invention, there is shown in the l0 drawings an embodiment that is presently preferred. It should be understood, however, that the invention is not limited to the precise arrangement and instrumentality shown. In the drawings:
Figure 1A illustrates a top view of the present invention.
15 Figures 1 B - 1 D illustrate a side view of the present invention.
Figures 2A - 2 E illustrate the present invention in operation.
Figure 3A illustrates an embodiment of the present invention incorporated into a wall of a tubular medical device.
Figure 3B illustrates an embodiment of the present invention incorporated into a planar 2o material that is attached to a wall of a tubular medical device.
Figure 4 illustrates an embodiment of the present invention incorporated into a medical device.
Figure 4A illustrates an embodiment of the present invention placed in a discrete location relative to scaffolding and wall elements of an implantable medical device.
25 Figure 5 illustrates an abdominal aortic aneurysm.
Figure 6 illustrates a stent-graft incorporating an embodiment of the present invention placed in the region of an abdominal aortic aneurysm.
Figures 7A - 7D illustrate the present invention being utilized to provide perfusion to side branches of a blood vessel.
3o Figure 7E illustrates an embodiment of the present invention serving as attachment means for another medical device.
Figures 8A - 8C illustrate the framework component of the present invention in various non-limiting shapes.
Figure 9 illustrates the framework component of the present invention in the form of an array.
35 Figure 10 illustrates the framework component of the present invention in the form of an array.
Figure 11 illustrates a method of constructing the breachable barrier material in an embodiment of the present invention.
Figure 12 is an exploded view of an embodiment of the present invention under construction.
Figure 13 is a perspective view of an embodiment of the present invention.
The accompanying diagrams include various anatomical structures and associated clinical pathologies that are identified as follows:
AA = Abdominal Aorta 1o RA = Renal Artery IA = Iliac Artery AAA = Abdominal Aortic Aneurysm DETAILED DESCRIPTION OF THE INVENTION
The present invention can be used in combination with a variety of implantable fluid-containing medical devices to establish fluid communication across a wall, or other partition, in the devices. In many situations, the present invention is employed at the time the medical device is implanted. In other instances, the present invention is accessed and utilized after 2o the medical device.has been implanted for a period of time. The present invention can also be used before the implant procedure begins.
Figure 1A is a top view of an embodiment of the present invention 10 incorporated into an implantable patch material 12. Figure 1 B is a side view of this embodiment generally illustrating the relationship of the components. In this embodiment, a framework 14 is surrounded by a layer of implantable polymeric material 18. The framework 14 delimits an opening 16 that is fully covered with a breachable barrier material 17. The polymer layer 18 is sandwiched between two layers of implantable patch material 12, 13 so as to reveal the framework 14, opening 16, and breachable barrier material 17 of the present invention. In similar embodiments of the present invention, the implantable patch material or other wall 3o components are considered part of the invention. In addition to implantable medical devices having planar configurations, implantable medical devices having tubular configurations are also suitable for use with the present invention. Tubular medical devices are generally cylindrical in shape and not confined to having parallel walls. In addition, tubular medical devices have geometries with at least one inlet and at least one outlet.
The shape of the framework 14 is chosen to provide structural support to the breachable barrier material 17 while it fully covers opening 16. The shape and composition of the framework also allows the framework to be readily deformed and displaced to peripheral regions of the opening to form a permanent framed aperture. The particular shape of the framework illustrated in Figure 1A, et. al., is preferred but not limiting. For example, Figures 8B and 8C illustrate frameworks having circular configurations 70 incorporating varying numbers of peaks 76 and valleys 78. It is also contemplated in the present invention that the distance between the peaks 76 and valleys 78 (i.e., amplitude) can be varied broadly, thereby enabling a wide range of framework geometries to be formed. In addition to enhancing support for the breachable barrier material with these framework designs, a wide range of aperture sizes can be achieved with these designs.
Supporting leg struts 74 can also be incorporated into the framework design to enhance attachment to 1o surrounding wall materials. Other non-circular configurations 79 of the framework 14 are also contemplated. Furthermore, Figures 9 and 10 illustrate that the framework can be in the form of an array of openings. These embodiments provide a choice of locations for the framed aperture as well as the number of framed apertures.
Figures 2A-2E illustrate the construct of Figures 1A and 1 B in use. Figure 2A
is a perspective view of the construct as it might appear at an implantation site.
Figure 2B shows a guide wire 20 from a catheter, or other device, having penetrated and breached the breachable barrier material 17. Figure 2C depicts an expandable balloon catheter 22 in a deflated state being introduced through the breached barrier material into opening 16 with guide wire 20. Figure 2D illustrates inflation of the expandable balloon catheter 22 and 2o deformation of framework 14. As the framework 14 is deformed, opening 16 is enlarged and expanded in area. Following deflation and removal of the balloon catheter, Figure 2E shows the resulting permanent aperture 24 framed with altered framework 14 in implantable patch material 12.
Figure 3A illustrates the present invention 15 as a component of a tubular vascular graft 30. In this embodiment, framework 14 delimiting opening 16 is fully covered by breachable barrier material 17 and incorporated into wall portion 32 of vascular graft 30.
When the invention is operated, fluid communication across wall portion 32 to luminal space 34 is established.
Figure 3B illustrates an embodiment of the present invention 19 having an 3o implantable patch material 11 component. The implantable patch material is attached to an implantable vascular prosthesis 30 by sewing. Other suitable means of attaching the present invention to a wall of an implantable medical device include, but are not limited to, adhering, ultrasonic or radio frequency welding, lamination, stapling, and covering the medical device with a membrane or film to include the present invention.
Figure 4 illustrates an embodiment of the present invention 44 incorporated into an implantable tubular endovascular device 40. In this embodiment, the endovascular device is a bifurcated design commonly used to treat aortic aneurysms and includes a main body, or trunk, portion 50 and two leg portions 52, 54. The endovascular device has a stent frame 42 and wall means 48. Several fully covered framework elements of the present invention are incorporated into the wall means 48 of the stent-graft 40. As seen in Figure 4, there is a longitudinal displacement between the present invention and the support elements (i.e., scaffolding) of the stent-graft. This embodiment of the present invention provides multiple sites for forming side branches in stent-grafts and other endovascular devices as means for providing selective perfusion and/or drainage of the implantation site.
In embodiments of the present invention used in combination with stent-grafts, and other implantable medical devices utilizing support elements (i.e., scaffolding), the 1o framework component of the present invention is preferably incorporated into the device separately from the support elements. As shown in Figure 4A, the framework of the present invention underlies and is discrete from the support elements of the implantable medical device. The location of the present invention is not limited to contact or close proximity to support elements or wall components of an implantable medical device. Indeed, the present 15 invention can be positioned in any desired location in an implantable medical device.
A clinical application of the embodiment illustrated in Figure 4 is depicted in Figures 5 and 6. A typical abdominal aortic aneurysm (AAA) is shown in Figure 5 with the proximal aorta (AA) leading to renal artery (RA) branches and distal iliac arteries (IAs). In cases where the disease condition or aortic anatomy does not provide sufficient healthy vessel 2o upon which to achieve device fixation at implant, it is often necessary to utilize the AA
segment proximal to the RAs. In this suprarenal implant position, an appropriate stent-graft 40 fixation can be achieved and effective AAA exclusion as shown in Figure 6.
In this configuration however, the barrier properties of the stent-graft wall 48 occlude blood flow to the branching RA on both sides. In order to achieve RA perfusion, one or more units 44 of 25 the present invention are selected and utilized.
The interventional procedure required to access and operate the present invention is illustrated in Figures 7A-7D. Following deployment of stent graft 40, a guide catheter 36 is positioned under fluoroscopic guidance to direct a guide-wire 20 toward the center of one of the plurality of available inventions 44 that is in appropriate alignment with the RA. Following 3o guide-wire 20 breach of the breachable barrier material 16, the framework 14 is altered in shape to the desired aperture size using a balloon catheter 22. Further inflation of the balloon 22 achieves the desired deformation of the framework 14 and formation of a permanent framed aperture 64 having a size appropriate for the RA. Once formed, the permanent framed aperture 64 provides for RA blood perfusion 62 in accordance with 35 normal AA blood flow 60.
The present invention can be constructed of a variety of implantable materials. The breachable barrier material has a composition, structure, and/or thickness sufficient to at least partially bar liquids, including blood and other physiological fluids, from crossing the material, yet have sufficient structural weakness to be readily breached, perforated, or otherwise structurally disrupted with surgical instruments, or the like. The breathable barrier material can be made of non-biodegradable polymers, bio-degradable polymers, and elastomers, either alone or in combination. Elastomers in the breathable barrier materials can augment uncovering of the fully covered opening following breach of the barrier material.
The breathable barrier material can be provided with filler materials that also augment breaching of the barrier material or assist in locating the invention at an implantation site.
Suitable surgical instruments or tools for use in breaching the barrier material at an io implantation site include, but are not limited to, guide-wires, Colapinto0 needles, Rotablators~, and other ablation instruments utilizing radio-frequency energy, ultrasonic sound, microwave energy, or laser light.
Suitable non-biodegradable polymers include, but are not limited to, polyester, polytetrafluoroethylene, polyamide, and polyurethane. The preferred material for the 15 breathable barrier material is a porous expanded, or stretched, polytetrafluoroethylene material. Suitable bio-degradable polymers include, but are not limited to, materials made of polymers or copolymers possessing one or more of the following monomeric components:
glycolide (glycolic acid); lactide (d-lactide, I-lactide, d,l-lactide);
trimethylene carbonate; p-dioxanone; caprolactone, and hydroxybutyrate, hydroxyvalerate. Elastomeric materials 2o suitable for use in the present invention include, but are not limited to, fluoroelastomers, polyurethane. Suitable filler materials for incorporation into the breathable barrier material include, but are not limited to, graphite, titanium oxide (Ti0), barium, vitamin E, gadolinium, lossy materials, and other radio-opaque compositions.
The breathable barrier material can be applied to the framework as a single layer or 2s in multiple layers. When using multiple layers of breathable barrier material, it is preferred to orient the individual layers in different directions (see e.g. Figure 11 ).
The framework is made of materials that are capable of supporting the breathable barrier material while the barrier material is fully covering the opening delimited by the framework. The materials of the framework permit the framework to be readily shaped, 3o reshaped, or otherwise altered in configuration while the invention is located at an implantation site. The framework can be made of malleable materials, plastically deformable materials, and/or self-expanding (i.e., super-elastic) metals or polymers.
When materials are used that do not lend themselves to visualization with fluoroscopy, x-ray imagining, magnetic resonance imaging, etc., radio-opaque or other imaging compounds can be introduced into 3s the framework materials.
The materials of the framework also need to be sufficiently resilient to provide permanent reinforcement of peripheral regions of the aperture under physiological to conditions. In addition to providing structural support to peripheral regions of the aperture portion of the invention, the framework component can serve as anchoring means for other medical devices 90 attached thereto (e.g., Figure 7E).
Suitable materials for the framework include, but are not limited to, implantable metals such as gold, silver, tantalum, tungsten, and chromium, implantable metal alloys such as stainless steel, nitinol metal, and implantable polymers such as polyurethanes, fluorinated ethylene propylene, and polytetrafluoroethylene. The framework can be made by molding, casting, laser cutting and/or laser machining, stamping, photo-etching, wire-forming, electrical discharge machining (EDM), bent wire techniques, or other suitable fabrication 1o method.
In embodiments of the present invention that include a patch, tube, or other walled component, essentially any implantable material can be used for the component.
Suitable materials include but are not limited to, implantable metals, implantable metal alloys, implantable polymers such as polyester (Dacron0), polyamide (Nylon), 15 polytetrafluoroethylene, silicone, and polyurethane.
The present invention can be constructed in a variety of ways. The invention can be made by attaching the breachable barrier material to the framework material with adhesives, heat, pressure, and/or ultrasonic welding. In turn, the breachable barrier material can be attached to an implantable medical device with similar methodologies. The invention can 2o also be incorporated into an implantable medical device by molding, sewing, wrapping with a film or membrane, and/or mechanical fixation.
An implantable medical device made of an expanded polytetrafluoroethylene (ePTFE) in the form of a tube or sheet can be supplied with an embodiment of the present invention by first cutting a hole in the ePTFE slightly smaller than the largest diameter of the 25 framework component. Next, a powder coating of fluorinated ethylene propylene (FEP) is applied to both sides of the framework material and the framework material placed over the hole in the ePTFE material. A suitably sized piece of breachable barrier material is placed over the framework component. Heat and pressure are applied to the combination to attach the materials together.
3o Another method of attaching the present invention to an implantable medical device involves applying an adhesive material, such a room temperature vulcanizing (RTV) silicone, to both sides of the framework material and pressing one side of the framework onto a wall of the medical device having a suitably sized hole formed therein. A suitable breachable barrier material is then pressed onto the other adhesive-coated side of the framework 35 component. Any excess barrier material is trimmed away from the framework to complete the installation.
Yet another method of attaching the present invention to an implantable medical device involves placing a framework component over a suitably sized hole in a wall of the medical device and wrapping one or more layers of a biocompatible film over the framework component. In this embodiment, the wrapped film layers) can also serve as the breachable barrier material. The film wrapping material can be further secured by heating the construction.
For implantable medical devices having a wall element in the form of a meshwork, the present invention can be attached to the medical device in such a way that the opening is accessibly through holes in the meshwork. In this embodiment, an adhesive-coated 1o framework material is placed on a breachable barrier material. Additional adhesive is placed on perimeter regions of the barrier material. A meshwork device is placed over this combination so the opening of the present invention is accessible through one or more holes in the meshwork. Pressure is applied to the construct to adhere the components together.
A preferred implantable medical device is a woven mesh material commercially available 15 from Davol, Inc. under the trade name Bard~ MarIexTM Mesh - Monofilament Knitted Polypropylene (Catalog No. 011265).
These construction methodologies are exemplary and are not intended to limit the scope of the present invention.
20 Examples Without intending to limit the scope of the present invention, the apparatus and method of production of the present invention may be better understood by referring to the following examples.
A planar sheet embodiment of the present invention, approximately 8.3cm (3.25") by 13.3cm (5.25"), was constructed as follows. A first layer of an expanded 3o polytetrafluoroethylene (ePTFE) sheet material having a thickness of about 0.4mm was obtained from the Medical Products Division of W.L. Gore & Associates, Inc., Flagstaff, AZ
under the tradename GORE-TEX~ Cardiovascular Patch as part number 1800610004 (Figure 12, part A1 ).
A second layer of a fluoro-elastomeric sheet material composed of a thermoplastic copolymer of tetrafluoroethylene (TFE) and perfluoro(methyl vinyl ether) (PMVE) was constructed by compression molding the crumb form of the copolymer at a temperature of about 250° C to form a sheet about 0.2mm (0.008") in thickness (Figure 12, part A3). The resulting material had the attributes described in TABLE 1 below.
A third layer of sheet material (Figure 12, part A4) is composed of ePTFE made according to US Patent 4,482,516, issued to Gore. The sheet material was approximately 0.17mm thick with an average fibril length of greater than about 10 microns.
A sheet of medical grade 316 stainless steel was obtained from Laserage Technologies, Inc., Waukegan, III. for use in constructing a framework. The framework was laser machined into an undulating pattern having a continuous, generally circular, ringed configuration (Figure 12, part A2). The thickness of the framework was about 0.4mm to (0.016"). The minimum distance between individual framework elements located opposite one another in the opening delimited by the framework was about 0.2mm (0.008").
These four components were aligned together as shown in Figure 12. Components 100, 102, 103, and 104 were placed between layers of high temperature padding material and aluminum plates (Figure 12, parts 105, 106). The aluminum plates were approximately 15.2cm (6") square and 0.062" thick. The high temperature padding material 105 was made of GORE-TEX~ Soft Tissue Patch having a thickness of about 2mm (0.079") available from the Medical Products Division of W.L. Gore & Associates, Inc., Flagstaff, AZ
as part number 1310015020. The assembly was placed in a heated Carver press and laminated together in the arrangement shown in Figure 12 for about 5 minutes, at about 200° C
with a pressure of 2o about 0.5Mpa (80 Ib/in2). Following the compression cycle in the press, the padding material was discarded.
A 4mm hole was then cut though all three layers of material at the center point of the reinforcement element using a 4mm sharpened coring punch. Four layers of high strength ePTFE film made according to US patent 5,476,589, issued to Bacino, were obtained and oriented at 90 degree angles with respect to one another (Figure C). A layer of discontinuous fluorinated ethylene propylene (FEP) coating was placed between each layer of ePTFE material. These combined materials were placed over the cutout hole and secured in place using a heated soldering iron applied around the outer perimeter of the cutout hole. Excess film material was than trimmed from the final assembly and the edges 3o tacked down thoroughly with the heated soldering iron. The resulting article is shown in Figure 13.
Table 1 Characteristic Target PMVE wt% about 60%
TFE wt% About 40%
100% Secant Modulus* About 2.1-2.2 MPa Softening Temperature < 275 C
Thermal Degradation Temp. >300 C
Melt Flow Index** ~ ~ >2.0 Durometer 60-80 Shore A
*as per ASTM D412-98, using %2 scale l ype w dogbone witn ~oummimm crossneaa speea and approximately 40mm grip separation.
**grams per 10 minutes, 10 kg, 325°C.
to This example describes a tubular vascular graft having the article of Example 1 incorporated into the wall of the tubular graft. The article of Example 1 was trimmed and sewn into a corresponding hole cut through the wall of an ePTFE vascular graft. The ePTFE
vascular graft was a GORE-TEX~ Vascular Graft available from the Medical Products Division of W.L. Gore & Associates, Inc., Flagstaff, AZ as part number SA1604.
The article 15 from Example 1 was sewn into the corresponding hole of the tubular construct with an ePTFE suture material obtained from Medical Products Division of W.L. Gore &
Associates, Inc. Flagstaff, AZ under the tradename GORE-TEX~ Suture as part number CV-5.
The resulting article is shown in Figure 3B.
2o Accurate and illustrative examples of the invention have been described in detail however, it is readily foreseen that numerous modifications may be made to these examples without departing from the nature and spirit or scope of the present invention.
Once the pulmonary circulation and functional ventricle are sufficiently developed, a subsequent procedure is performed wherein the blood going to the right ventricle is to bypassed by routing the blood in the Inferior Vena Cava (IVC) directly to the PA by way of a baffle or tube connecting the IVC to the PA. At the time of this procedure, a small hole is typically created in the side of the connection tube to allow some flow of blood into the right ventricle. This small hole is considered a temporary connection that reduces the work for the remaining ventricle when pulmonary vascular resistance is elevated. Bridges, N.D., Mayer, 15 J.E., Lock, J.E., Jonas, R.A., Hanley, F.L., Keane, J.F., Perry, S.B., Castaneda, A.R. "Effect of baffle fenestration on outcome of the modified Fontan operation."
Circulation 86:1762-9 (1992). ' The final surgical procedure involves either surgical closure or transcatheter occlusion of the temporary hole in the IVC to PA connector tube. This multi-staged 2o conventional surgical approach for patients with complex congenital heart disease is not optimal as it puts patients at additional risk of morbidity and mortality with each subsequent surgical intervention. This risk may be reduced if the first surgical intervention can set the stage for a future minimally invasive procedure that eliminates the need for additional open-heart surgery.
25 Various devices and design modifications have been proposed in an effort to provide access to anatomical structures surrounding the device or to internal spaces of the device.
U.S. Pat. No. 6,428,565, issued to Wisselink, and U.S. Pat. No. 6,395,018, issued to Castaneda, each relate to stent-graft systems with pre-formed apertures to allow for side-branch access. Neither of these devices have apertures that are closed at the time of initial 30 implant.
U.S. Pat. No. 6,398,803, issued to Layne, et. al., relates to partially covered stents having various patterns of open apertures along the length of the device. As with the Wisselink and Castaneda devices, the apertures are fully formed prior to deployment of the device.
35 U.S. Pat. No. 6,432,127, issued to Kim, et. al., discloses formation of an aperture in the wall of a vascular conduit through the use of a cutting tool. The conduit does not provide a deformable framework encompassing the aperture formation site. As a result, targeting the precise location of the region in which to create the aperture is difficult to visualize using conventional imaging techniques. Moreover, the aperture is not reinforced along its peripheral regions once the aperture is formed. The absence of a framework delimiting the aperture formation site precludes precise sizing of the aperture during its formation.
There remains a need for a device that initially maintains the continuity and fluid-retaining properties of a wall portion of an implantable medical device, while providing means for forming a permanent aperture in the medical device. Such a device would permit custom sizing of the aperture in situ at the implant site during surgery.
to SUMMARY OF THE INVENTION
The present invention is directed to a device that is amenable to transmural fenestration. In particular, the present invention permits a permanent framed aperture to be formed in a wall, or similar partition, of implantable medical devices as a means for 15 establishing and maintaining fluid communication across the wall of the medical device following implantation. The present invention provides a breachable barrier material that initially maintains the continuity and any fluid-retaining properties of the wall of the medical device. The breachable barrier material fully covers an opening delimited by a framework.
In use, the breachable barrier material is breached with a surgical instrument and the shape 20 of the framework altered to enlarge, or otherwise alter, the area of the opening. In the process, the opening becomes uncovered and accessible to flow of fluid through the opening. The altered framework provides structural reinforcement to peripheral regions (e.g., circumferential) of the enlarged opening and forms a permanent aperture in the wall of the medical device. The altered framework can also be used to provide a secure anchoring 25 site for ancillary medical devices. The permanent aperture can be formed in the wall of the implantable medical device at the time of surgical or catheter-based intervention or at a later date through the use of interventional or surgical techniques.
The present invention is particularly suited for use with vascular prostheses, and other implantable medical devices providing fluid containment or fluid partitioning, that can 30 benefit from the formation of one or more permanent apertures in the devices at the implantation site. With stent-grafts spanning an aneurysm, for example, the invention can provide a framed aperture in the wall of the stent-graft for side-branches or drainage sites.
Vascular grafts can be bypassed or bifurcated in-situ with the present invention. The invention can also be used with surgically implanted cardiovascular patches to provide 35 perfusion or other access to the heart and vascular system.
The present invention can be added to an implantable medical device following its construction, or included in the manufacture of the device as an integral component. The breachable barrier material of the present invention is made of implantable polymers that are readily breached, perforated, or otherwise structurally disrupted with surgical instruments.
The breachable barrier material can also be made of polymers that are structurally disrupted through degradation and absorption by the body of the implant recipient. The polymers of the breachable barrier material can be incorporated with filler materials to assist in breaching the barrier material or to facilitate visualization of the aperture region in an implant recipient.
The framework is made of implantable metallic or polymeric materials that can be altered in shape. These framework materials can be deformed or otherwise altered in shape with surgical instruments or have shape-memory properties that permit the framework to 1o assume different shapes without the use of an instrument. The framework materials are shaped in various ways to assist in the combined roles of structurally reinforcing the breachable barrier material and the opening, being capable of reconfiguration, and providing a permanent framed aperture.
In one surgical method, an implantable medical device utilizing the present invention 15 is placed at a surgical site with conventional or interventional surgical techniques. Once the correct position of the medical device is confirmed, a catheter guide-wire, or other surgical instrument, is used to breach the breachable barrier material and begin to uncover the covered opening. An expandable balloon catheter in a deflated configuration is then inserted into the partially uncovered opening and inflated. As the balloon catheter is inflated, 2o it expands in diameter, altering the shape of the framework and displacing the remaining barrier material from the area of the opening. When the framework has been reconfigured as desired, the balloon catheter is deflated and removed from the opening.
This leaves a permanent framed aperture in the wall of the medical device. The permanent aperture can provide immediate therapies and surgical remedies, such as branch vessel perfusion, or co-25 operate with other medical devices.
In one embodiment, the present invention is an implantable medical device comprising a framework delimiting an opening having a first area and a breachable barrier material fully covering said opening, wherein a permanent aperture having a second area is formed following breach of said breachable material and said framework is adaptable to be 3o altered in shape.
In another embodiment, the present invention is an implantable medical device comprising a continuous wall, at least one framework in said wall delimiting an opening having a first area, a breachable barrier material fully covering said opening, wherein a permanent aperture having a second area is formed following breach of said breachable 35 material and said framework is adaptable to be altered in shape and have a reinforced peripheral region in said continuous wall.
Further aspects and advantages of the present invention will be apparent to those skilled in the art after reading and understanding the detailed description of preferred embodiments set forth hereinbelow and after viewing the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing summary, as well as the following detailed description of a preferred embodiment of the invention, will be better understood when read in conjunction with the appended drawings. For purposes of illustrating the invention, there is shown in the l0 drawings an embodiment that is presently preferred. It should be understood, however, that the invention is not limited to the precise arrangement and instrumentality shown. In the drawings:
Figure 1A illustrates a top view of the present invention.
15 Figures 1 B - 1 D illustrate a side view of the present invention.
Figures 2A - 2 E illustrate the present invention in operation.
Figure 3A illustrates an embodiment of the present invention incorporated into a wall of a tubular medical device.
Figure 3B illustrates an embodiment of the present invention incorporated into a planar 2o material that is attached to a wall of a tubular medical device.
Figure 4 illustrates an embodiment of the present invention incorporated into a medical device.
Figure 4A illustrates an embodiment of the present invention placed in a discrete location relative to scaffolding and wall elements of an implantable medical device.
25 Figure 5 illustrates an abdominal aortic aneurysm.
Figure 6 illustrates a stent-graft incorporating an embodiment of the present invention placed in the region of an abdominal aortic aneurysm.
Figures 7A - 7D illustrate the present invention being utilized to provide perfusion to side branches of a blood vessel.
3o Figure 7E illustrates an embodiment of the present invention serving as attachment means for another medical device.
Figures 8A - 8C illustrate the framework component of the present invention in various non-limiting shapes.
Figure 9 illustrates the framework component of the present invention in the form of an array.
35 Figure 10 illustrates the framework component of the present invention in the form of an array.
Figure 11 illustrates a method of constructing the breachable barrier material in an embodiment of the present invention.
Figure 12 is an exploded view of an embodiment of the present invention under construction.
Figure 13 is a perspective view of an embodiment of the present invention.
The accompanying diagrams include various anatomical structures and associated clinical pathologies that are identified as follows:
AA = Abdominal Aorta 1o RA = Renal Artery IA = Iliac Artery AAA = Abdominal Aortic Aneurysm DETAILED DESCRIPTION OF THE INVENTION
The present invention can be used in combination with a variety of implantable fluid-containing medical devices to establish fluid communication across a wall, or other partition, in the devices. In many situations, the present invention is employed at the time the medical device is implanted. In other instances, the present invention is accessed and utilized after 2o the medical device.has been implanted for a period of time. The present invention can also be used before the implant procedure begins.
Figure 1A is a top view of an embodiment of the present invention 10 incorporated into an implantable patch material 12. Figure 1 B is a side view of this embodiment generally illustrating the relationship of the components. In this embodiment, a framework 14 is surrounded by a layer of implantable polymeric material 18. The framework 14 delimits an opening 16 that is fully covered with a breachable barrier material 17. The polymer layer 18 is sandwiched between two layers of implantable patch material 12, 13 so as to reveal the framework 14, opening 16, and breachable barrier material 17 of the present invention. In similar embodiments of the present invention, the implantable patch material or other wall 3o components are considered part of the invention. In addition to implantable medical devices having planar configurations, implantable medical devices having tubular configurations are also suitable for use with the present invention. Tubular medical devices are generally cylindrical in shape and not confined to having parallel walls. In addition, tubular medical devices have geometries with at least one inlet and at least one outlet.
The shape of the framework 14 is chosen to provide structural support to the breachable barrier material 17 while it fully covers opening 16. The shape and composition of the framework also allows the framework to be readily deformed and displaced to peripheral regions of the opening to form a permanent framed aperture. The particular shape of the framework illustrated in Figure 1A, et. al., is preferred but not limiting. For example, Figures 8B and 8C illustrate frameworks having circular configurations 70 incorporating varying numbers of peaks 76 and valleys 78. It is also contemplated in the present invention that the distance between the peaks 76 and valleys 78 (i.e., amplitude) can be varied broadly, thereby enabling a wide range of framework geometries to be formed. In addition to enhancing support for the breachable barrier material with these framework designs, a wide range of aperture sizes can be achieved with these designs.
Supporting leg struts 74 can also be incorporated into the framework design to enhance attachment to 1o surrounding wall materials. Other non-circular configurations 79 of the framework 14 are also contemplated. Furthermore, Figures 9 and 10 illustrate that the framework can be in the form of an array of openings. These embodiments provide a choice of locations for the framed aperture as well as the number of framed apertures.
Figures 2A-2E illustrate the construct of Figures 1A and 1 B in use. Figure 2A
is a perspective view of the construct as it might appear at an implantation site.
Figure 2B shows a guide wire 20 from a catheter, or other device, having penetrated and breached the breachable barrier material 17. Figure 2C depicts an expandable balloon catheter 22 in a deflated state being introduced through the breached barrier material into opening 16 with guide wire 20. Figure 2D illustrates inflation of the expandable balloon catheter 22 and 2o deformation of framework 14. As the framework 14 is deformed, opening 16 is enlarged and expanded in area. Following deflation and removal of the balloon catheter, Figure 2E shows the resulting permanent aperture 24 framed with altered framework 14 in implantable patch material 12.
Figure 3A illustrates the present invention 15 as a component of a tubular vascular graft 30. In this embodiment, framework 14 delimiting opening 16 is fully covered by breachable barrier material 17 and incorporated into wall portion 32 of vascular graft 30.
When the invention is operated, fluid communication across wall portion 32 to luminal space 34 is established.
Figure 3B illustrates an embodiment of the present invention 19 having an 3o implantable patch material 11 component. The implantable patch material is attached to an implantable vascular prosthesis 30 by sewing. Other suitable means of attaching the present invention to a wall of an implantable medical device include, but are not limited to, adhering, ultrasonic or radio frequency welding, lamination, stapling, and covering the medical device with a membrane or film to include the present invention.
Figure 4 illustrates an embodiment of the present invention 44 incorporated into an implantable tubular endovascular device 40. In this embodiment, the endovascular device is a bifurcated design commonly used to treat aortic aneurysms and includes a main body, or trunk, portion 50 and two leg portions 52, 54. The endovascular device has a stent frame 42 and wall means 48. Several fully covered framework elements of the present invention are incorporated into the wall means 48 of the stent-graft 40. As seen in Figure 4, there is a longitudinal displacement between the present invention and the support elements (i.e., scaffolding) of the stent-graft. This embodiment of the present invention provides multiple sites for forming side branches in stent-grafts and other endovascular devices as means for providing selective perfusion and/or drainage of the implantation site.
In embodiments of the present invention used in combination with stent-grafts, and other implantable medical devices utilizing support elements (i.e., scaffolding), the 1o framework component of the present invention is preferably incorporated into the device separately from the support elements. As shown in Figure 4A, the framework of the present invention underlies and is discrete from the support elements of the implantable medical device. The location of the present invention is not limited to contact or close proximity to support elements or wall components of an implantable medical device. Indeed, the present 15 invention can be positioned in any desired location in an implantable medical device.
A clinical application of the embodiment illustrated in Figure 4 is depicted in Figures 5 and 6. A typical abdominal aortic aneurysm (AAA) is shown in Figure 5 with the proximal aorta (AA) leading to renal artery (RA) branches and distal iliac arteries (IAs). In cases where the disease condition or aortic anatomy does not provide sufficient healthy vessel 2o upon which to achieve device fixation at implant, it is often necessary to utilize the AA
segment proximal to the RAs. In this suprarenal implant position, an appropriate stent-graft 40 fixation can be achieved and effective AAA exclusion as shown in Figure 6.
In this configuration however, the barrier properties of the stent-graft wall 48 occlude blood flow to the branching RA on both sides. In order to achieve RA perfusion, one or more units 44 of 25 the present invention are selected and utilized.
The interventional procedure required to access and operate the present invention is illustrated in Figures 7A-7D. Following deployment of stent graft 40, a guide catheter 36 is positioned under fluoroscopic guidance to direct a guide-wire 20 toward the center of one of the plurality of available inventions 44 that is in appropriate alignment with the RA. Following 3o guide-wire 20 breach of the breachable barrier material 16, the framework 14 is altered in shape to the desired aperture size using a balloon catheter 22. Further inflation of the balloon 22 achieves the desired deformation of the framework 14 and formation of a permanent framed aperture 64 having a size appropriate for the RA. Once formed, the permanent framed aperture 64 provides for RA blood perfusion 62 in accordance with 35 normal AA blood flow 60.
The present invention can be constructed of a variety of implantable materials. The breachable barrier material has a composition, structure, and/or thickness sufficient to at least partially bar liquids, including blood and other physiological fluids, from crossing the material, yet have sufficient structural weakness to be readily breached, perforated, or otherwise structurally disrupted with surgical instruments, or the like. The breathable barrier material can be made of non-biodegradable polymers, bio-degradable polymers, and elastomers, either alone or in combination. Elastomers in the breathable barrier materials can augment uncovering of the fully covered opening following breach of the barrier material.
The breathable barrier material can be provided with filler materials that also augment breaching of the barrier material or assist in locating the invention at an implantation site.
Suitable surgical instruments or tools for use in breaching the barrier material at an io implantation site include, but are not limited to, guide-wires, Colapinto0 needles, Rotablators~, and other ablation instruments utilizing radio-frequency energy, ultrasonic sound, microwave energy, or laser light.
Suitable non-biodegradable polymers include, but are not limited to, polyester, polytetrafluoroethylene, polyamide, and polyurethane. The preferred material for the 15 breathable barrier material is a porous expanded, or stretched, polytetrafluoroethylene material. Suitable bio-degradable polymers include, but are not limited to, materials made of polymers or copolymers possessing one or more of the following monomeric components:
glycolide (glycolic acid); lactide (d-lactide, I-lactide, d,l-lactide);
trimethylene carbonate; p-dioxanone; caprolactone, and hydroxybutyrate, hydroxyvalerate. Elastomeric materials 2o suitable for use in the present invention include, but are not limited to, fluoroelastomers, polyurethane. Suitable filler materials for incorporation into the breathable barrier material include, but are not limited to, graphite, titanium oxide (Ti0), barium, vitamin E, gadolinium, lossy materials, and other radio-opaque compositions.
The breathable barrier material can be applied to the framework as a single layer or 2s in multiple layers. When using multiple layers of breathable barrier material, it is preferred to orient the individual layers in different directions (see e.g. Figure 11 ).
The framework is made of materials that are capable of supporting the breathable barrier material while the barrier material is fully covering the opening delimited by the framework. The materials of the framework permit the framework to be readily shaped, 3o reshaped, or otherwise altered in configuration while the invention is located at an implantation site. The framework can be made of malleable materials, plastically deformable materials, and/or self-expanding (i.e., super-elastic) metals or polymers.
When materials are used that do not lend themselves to visualization with fluoroscopy, x-ray imagining, magnetic resonance imaging, etc., radio-opaque or other imaging compounds can be introduced into 3s the framework materials.
The materials of the framework also need to be sufficiently resilient to provide permanent reinforcement of peripheral regions of the aperture under physiological to conditions. In addition to providing structural support to peripheral regions of the aperture portion of the invention, the framework component can serve as anchoring means for other medical devices 90 attached thereto (e.g., Figure 7E).
Suitable materials for the framework include, but are not limited to, implantable metals such as gold, silver, tantalum, tungsten, and chromium, implantable metal alloys such as stainless steel, nitinol metal, and implantable polymers such as polyurethanes, fluorinated ethylene propylene, and polytetrafluoroethylene. The framework can be made by molding, casting, laser cutting and/or laser machining, stamping, photo-etching, wire-forming, electrical discharge machining (EDM), bent wire techniques, or other suitable fabrication 1o method.
In embodiments of the present invention that include a patch, tube, or other walled component, essentially any implantable material can be used for the component.
Suitable materials include but are not limited to, implantable metals, implantable metal alloys, implantable polymers such as polyester (Dacron0), polyamide (Nylon), 15 polytetrafluoroethylene, silicone, and polyurethane.
The present invention can be constructed in a variety of ways. The invention can be made by attaching the breachable barrier material to the framework material with adhesives, heat, pressure, and/or ultrasonic welding. In turn, the breachable barrier material can be attached to an implantable medical device with similar methodologies. The invention can 2o also be incorporated into an implantable medical device by molding, sewing, wrapping with a film or membrane, and/or mechanical fixation.
An implantable medical device made of an expanded polytetrafluoroethylene (ePTFE) in the form of a tube or sheet can be supplied with an embodiment of the present invention by first cutting a hole in the ePTFE slightly smaller than the largest diameter of the 25 framework component. Next, a powder coating of fluorinated ethylene propylene (FEP) is applied to both sides of the framework material and the framework material placed over the hole in the ePTFE material. A suitably sized piece of breachable barrier material is placed over the framework component. Heat and pressure are applied to the combination to attach the materials together.
3o Another method of attaching the present invention to an implantable medical device involves applying an adhesive material, such a room temperature vulcanizing (RTV) silicone, to both sides of the framework material and pressing one side of the framework onto a wall of the medical device having a suitably sized hole formed therein. A suitable breachable barrier material is then pressed onto the other adhesive-coated side of the framework 35 component. Any excess barrier material is trimmed away from the framework to complete the installation.
Yet another method of attaching the present invention to an implantable medical device involves placing a framework component over a suitably sized hole in a wall of the medical device and wrapping one or more layers of a biocompatible film over the framework component. In this embodiment, the wrapped film layers) can also serve as the breachable barrier material. The film wrapping material can be further secured by heating the construction.
For implantable medical devices having a wall element in the form of a meshwork, the present invention can be attached to the medical device in such a way that the opening is accessibly through holes in the meshwork. In this embodiment, an adhesive-coated 1o framework material is placed on a breachable barrier material. Additional adhesive is placed on perimeter regions of the barrier material. A meshwork device is placed over this combination so the opening of the present invention is accessible through one or more holes in the meshwork. Pressure is applied to the construct to adhere the components together.
A preferred implantable medical device is a woven mesh material commercially available 15 from Davol, Inc. under the trade name Bard~ MarIexTM Mesh - Monofilament Knitted Polypropylene (Catalog No. 011265).
These construction methodologies are exemplary and are not intended to limit the scope of the present invention.
20 Examples Without intending to limit the scope of the present invention, the apparatus and method of production of the present invention may be better understood by referring to the following examples.
A planar sheet embodiment of the present invention, approximately 8.3cm (3.25") by 13.3cm (5.25"), was constructed as follows. A first layer of an expanded 3o polytetrafluoroethylene (ePTFE) sheet material having a thickness of about 0.4mm was obtained from the Medical Products Division of W.L. Gore & Associates, Inc., Flagstaff, AZ
under the tradename GORE-TEX~ Cardiovascular Patch as part number 1800610004 (Figure 12, part A1 ).
A second layer of a fluoro-elastomeric sheet material composed of a thermoplastic copolymer of tetrafluoroethylene (TFE) and perfluoro(methyl vinyl ether) (PMVE) was constructed by compression molding the crumb form of the copolymer at a temperature of about 250° C to form a sheet about 0.2mm (0.008") in thickness (Figure 12, part A3). The resulting material had the attributes described in TABLE 1 below.
A third layer of sheet material (Figure 12, part A4) is composed of ePTFE made according to US Patent 4,482,516, issued to Gore. The sheet material was approximately 0.17mm thick with an average fibril length of greater than about 10 microns.
A sheet of medical grade 316 stainless steel was obtained from Laserage Technologies, Inc., Waukegan, III. for use in constructing a framework. The framework was laser machined into an undulating pattern having a continuous, generally circular, ringed configuration (Figure 12, part A2). The thickness of the framework was about 0.4mm to (0.016"). The minimum distance between individual framework elements located opposite one another in the opening delimited by the framework was about 0.2mm (0.008").
These four components were aligned together as shown in Figure 12. Components 100, 102, 103, and 104 were placed between layers of high temperature padding material and aluminum plates (Figure 12, parts 105, 106). The aluminum plates were approximately 15.2cm (6") square and 0.062" thick. The high temperature padding material 105 was made of GORE-TEX~ Soft Tissue Patch having a thickness of about 2mm (0.079") available from the Medical Products Division of W.L. Gore & Associates, Inc., Flagstaff, AZ
as part number 1310015020. The assembly was placed in a heated Carver press and laminated together in the arrangement shown in Figure 12 for about 5 minutes, at about 200° C
with a pressure of 2o about 0.5Mpa (80 Ib/in2). Following the compression cycle in the press, the padding material was discarded.
A 4mm hole was then cut though all three layers of material at the center point of the reinforcement element using a 4mm sharpened coring punch. Four layers of high strength ePTFE film made according to US patent 5,476,589, issued to Bacino, were obtained and oriented at 90 degree angles with respect to one another (Figure C). A layer of discontinuous fluorinated ethylene propylene (FEP) coating was placed between each layer of ePTFE material. These combined materials were placed over the cutout hole and secured in place using a heated soldering iron applied around the outer perimeter of the cutout hole. Excess film material was than trimmed from the final assembly and the edges 3o tacked down thoroughly with the heated soldering iron. The resulting article is shown in Figure 13.
Table 1 Characteristic Target PMVE wt% about 60%
TFE wt% About 40%
100% Secant Modulus* About 2.1-2.2 MPa Softening Temperature < 275 C
Thermal Degradation Temp. >300 C
Melt Flow Index** ~ ~ >2.0 Durometer 60-80 Shore A
*as per ASTM D412-98, using %2 scale l ype w dogbone witn ~oummimm crossneaa speea and approximately 40mm grip separation.
**grams per 10 minutes, 10 kg, 325°C.
to This example describes a tubular vascular graft having the article of Example 1 incorporated into the wall of the tubular graft. The article of Example 1 was trimmed and sewn into a corresponding hole cut through the wall of an ePTFE vascular graft. The ePTFE
vascular graft was a GORE-TEX~ Vascular Graft available from the Medical Products Division of W.L. Gore & Associates, Inc., Flagstaff, AZ as part number SA1604.
The article 15 from Example 1 was sewn into the corresponding hole of the tubular construct with an ePTFE suture material obtained from Medical Products Division of W.L. Gore &
Associates, Inc. Flagstaff, AZ under the tradename GORE-TEX~ Suture as part number CV-5.
The resulting article is shown in Figure 3B.
2o Accurate and illustrative examples of the invention have been described in detail however, it is readily foreseen that numerous modifications may be made to these examples without departing from the nature and spirit or scope of the present invention.
Claims (19)
1. A medical device amenable to fenestration comprising:
a polymeric wall material;
a framework adapted to be permanently deformable incorporated in said polymeric wall material;
wherein said framework has a first configuration delimiting an opening having a first area;
a readily breachable polymeric barrier material fully covering said opening when said framework is in said first configuration;
wherein said framework is adapted to assume a second configuration delimiting an opening having an area greater than said first area upon breach of said readily breachable polymeric barrier material and deformation of said deformable framework; and wherein said framework is incorporated in said polymeric wall material separately from any support elements utilized in said device.
a polymeric wall material;
a framework adapted to be permanently deformable incorporated in said polymeric wall material;
wherein said framework has a first configuration delimiting an opening having a first area;
a readily breachable polymeric barrier material fully covering said opening when said framework is in said first configuration;
wherein said framework is adapted to assume a second configuration delimiting an opening having an area greater than said first area upon breach of said readily breachable polymeric barrier material and deformation of said deformable framework; and wherein said framework is incorporated in said polymeric wall material separately from any support elements utilized in said device.
2. The implantable medical device of claim 1 wherein said polymeric wall material has a planar geometry.
3. The implantable medical device of claim 1 wherein said polymeric wall material has a tubular geometry.
4. The implantable medical device of claim I wherein said polymeric wall material is a vascular prosthesis.
5. The implantable medical device of claim 4 wherein said vascular prosthesis is a vascular graft.
6. The implantable medical device of claim 4 wherein said vascular prosthesis is a surgical patch.
7. The implantable medical device of claim 4 wherein said vascular prosthesis is a stent-graft.
8. The implantable medical device of claim 7 wherein said device is distinct from support elements of said stent-graft.
9. The implantable medical device of claim 1 wherein the device is a component of a vascular prosthesis.
10. The implantable medical device of claim 9 wherein said vascular prosthesis is a stent-graft.
11. The implantable medical device of claim 10 wherein said device is distinct from support elements of said stent-graft.
12. The implantable medical device of claim 1 wherein said polymeric wall material comprises a fluoropolymer.
13. The implantable medical device of claim 12 wherein said fluoropolymer is a polytetrafluoroethylene material.
14. The implantable medical device of claim I wherein said framework is made of an implantable metal.
15. The implantable medical device of claim 1 wherein said breachable barrier material comprises a fluoropolymer.
16. The implantable medical device of claim 15 wherein said fluoropolymer is a polytetrafluoroethylene material.
17. The implantable medical device of claim 1 wherein said breachable barrier material comprises a bio-degradable material.
18. The implantable medical device of claim 1 wherein said breachable barrier material includes a filler material.
19. The implantable medical device of claim 1 wherein said breachable barrier material comprises an elastomer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/251,031 | 2002-09-20 | ||
US10/251,031 US20040059406A1 (en) | 2002-09-20 | 2002-09-20 | Medical device amenable to fenestration |
PCT/US2003/029200 WO2004026181A1 (en) | 2002-09-20 | 2003-09-16 | Medical device amenable to fenestration |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2498176A1 CA2498176A1 (en) | 2004-04-01 |
CA2498176C true CA2498176C (en) | 2009-05-12 |
Family
ID=31992633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002498176A Expired - Lifetime CA2498176C (en) | 2002-09-20 | 2003-09-16 | Medical device amenable to fenestration |
Country Status (8)
Country | Link |
---|---|
US (2) | US20040059406A1 (en) |
EP (1) | EP1539037B1 (en) |
JP (1) | JP4571498B2 (en) |
AT (1) | ATE311834T1 (en) |
AU (1) | AU2003272473B2 (en) |
CA (1) | CA2498176C (en) |
DE (1) | DE60302674T2 (en) |
WO (1) | WO2004026181A1 (en) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7341598B2 (en) | 1999-01-13 | 2008-03-11 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US6599316B2 (en) | 1996-11-04 | 2003-07-29 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
EP1723931B1 (en) * | 1996-11-04 | 2012-01-04 | Advanced Stent Technologies, Inc. | Extendible stent apparatus and method for deploying the same |
US6325826B1 (en) * | 1998-01-14 | 2001-12-04 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US6835203B1 (en) | 1996-11-04 | 2004-12-28 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US8257425B2 (en) * | 1999-01-13 | 2012-09-04 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
EP1152711B1 (en) * | 1999-01-27 | 2005-07-06 | Boston Scientific Limited | Bifurcation stent delivery system |
WO2001021095A2 (en) * | 1999-09-23 | 2001-03-29 | Advanced Stent Technologies, Inc. | Bifurcation stent system and method |
WO2002067653A2 (en) | 2001-02-26 | 2002-09-06 | Scimed Life Systems, Inc. | Bifurcated stent and delivery system |
KR100893070B1 (en) * | 2002-09-19 | 2009-04-17 | 엘지전자 주식회사 | Method and apparatus for providing and receiving multicast service in a radio communication system |
US7959671B2 (en) * | 2002-11-05 | 2011-06-14 | Merit Medical Systems, Inc. | Differential covering and coating methods |
US7637942B2 (en) * | 2002-11-05 | 2009-12-29 | Merit Medical Systems, Inc. | Coated stent with geometry determinated functionality and method of making the same |
US7875068B2 (en) * | 2002-11-05 | 2011-01-25 | Merit Medical Systems, Inc. | Removable biliary stent |
US9125733B2 (en) | 2003-01-14 | 2015-09-08 | The Cleveland Clinic Foundation | Branched vessel endoluminal device |
CA2512610C (en) * | 2003-01-14 | 2008-12-23 | The Cleveland Clinic Foundation | Branched vessel endoluminal device |
US8298280B2 (en) | 2003-08-21 | 2012-10-30 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US8808351B2 (en) * | 2003-10-10 | 2014-08-19 | Cook Medical Technologies Llc | Stretchable prosthesis fenestration |
JP4406649B2 (en) * | 2003-10-10 | 2010-02-03 | ザ クリーブランド クリニック ファウンデイション | Intraluminal prosthesis for interconnection module related applications |
US9078780B2 (en) * | 2003-11-08 | 2015-07-14 | Cook Medical Technologies Llc | Balloon flareable branch vessel prosthesis and method |
US8007528B2 (en) * | 2004-03-17 | 2011-08-30 | Boston Scientific Scimed, Inc. | Bifurcated stent |
ATE491416T1 (en) | 2004-03-31 | 2011-01-15 | Cook Inc | STENT DEPOSITION DEVICE |
US8048140B2 (en) | 2004-03-31 | 2011-11-01 | Cook Medical Technologies Llc | Fenestrated intraluminal stent system |
WO2005122959A2 (en) | 2004-06-08 | 2005-12-29 | Advanced Stent Technologies, Inc. | Stent with protruding branch portion for bifurcated vessels |
AU2005262541B2 (en) * | 2004-06-16 | 2011-04-21 | Cook Incorporated | Thoracic deployment device and stent graft |
US8062214B2 (en) | 2004-08-27 | 2011-11-22 | Smith & Nephew, Inc. | Tissue resecting system |
US9427340B2 (en) * | 2004-12-14 | 2016-08-30 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
WO2006124824A1 (en) * | 2005-05-13 | 2006-11-23 | Alveolus, Inc. | Drainage stent and associated method |
US8317855B2 (en) * | 2005-05-26 | 2012-11-27 | Boston Scientific Scimed, Inc. | Crimpable and expandable side branch cell |
US20060271161A1 (en) * | 2005-05-26 | 2006-11-30 | Boston Scientific Scimed, Inc. | Selective treatment of stent side branch petals |
US8480728B2 (en) * | 2005-05-26 | 2013-07-09 | Boston Scientific Scimed, Inc. | Stent side branch deployment initiation geometry |
DE102005029049A1 (en) * | 2005-06-21 | 2006-12-28 | Charité - Universitätsmedizin Berlin | Stent e.g. for implanting in human or animal vessel, has hollow cylindrical body with braiding around periphery of it and braiding has large opening enabling inside of hollow cylindrical body to be accessed by peripheral surface |
US8043366B2 (en) * | 2005-09-08 | 2011-10-25 | Boston Scientific Scimed, Inc. | Overlapping stent |
US7731741B2 (en) | 2005-09-08 | 2010-06-08 | Boston Scientific Scimed, Inc. | Inflatable bifurcation stent |
US8038706B2 (en) * | 2005-09-08 | 2011-10-18 | Boston Scientific Scimed, Inc. | Crown stent assembly |
US20070112418A1 (en) | 2005-11-14 | 2007-05-17 | Boston Scientific Scimed, Inc. | Stent with spiral side-branch support designs |
US20070123970A1 (en) * | 2005-11-29 | 2007-05-31 | Boston Scientific Scimed, Inc. | Bifurcation stent with overlapping crimped struts |
US8343211B2 (en) * | 2005-12-14 | 2013-01-01 | Boston Scientific Scimed, Inc. | Connectors for bifurcated stent |
US8435284B2 (en) * | 2005-12-14 | 2013-05-07 | Boston Scientific Scimed, Inc. | Telescoping bifurcated stent |
US20070142904A1 (en) * | 2005-12-20 | 2007-06-21 | Boston Scientific Scimed, Inc. | Bifurcated stent with multiple locations for side branch access |
US7540881B2 (en) | 2005-12-22 | 2009-06-02 | Boston Scientific Scimed, Inc. | Bifurcation stent pattern |
US8778008B2 (en) * | 2006-01-13 | 2014-07-15 | Aga Medical Corporation | Intravascular deliverable stent for reinforcement of vascular abnormalities |
US8900287B2 (en) * | 2006-01-13 | 2014-12-02 | Aga Medical Corporation | Intravascular deliverable stent for reinforcement of abdominal aortic aneurysm |
US20070208256A1 (en) * | 2006-03-03 | 2007-09-06 | Medtronic Vascular, Inc. | Multiple Branch Tubular Prosthesis and Methods |
US20070208415A1 (en) * | 2006-03-06 | 2007-09-06 | Kevin Grotheim | Bifurcated stent with controlled drug delivery |
US20070208411A1 (en) * | 2006-03-06 | 2007-09-06 | Boston Scientific Scimed, Inc. | Bifurcated stent with surface area gradient |
US7833264B2 (en) * | 2006-03-06 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent |
US20070208419A1 (en) * | 2006-03-06 | 2007-09-06 | Boston Scientific Scimed, Inc. | Bifurcation stent with uniform side branch projection |
US8298278B2 (en) * | 2006-03-07 | 2012-10-30 | Boston Scientific Scimed, Inc. | Bifurcated stent with improvement securement |
US20070233233A1 (en) * | 2006-03-31 | 2007-10-04 | Boston Scientific Scimed, Inc | Tethered expansion columns for controlled stent expansion |
US9707113B2 (en) * | 2006-04-19 | 2017-07-18 | Cook Medical Technologies Llc | Twin bifurcated stent graft |
DE102006024245A1 (en) * | 2006-05-23 | 2007-08-02 | Siemens Ag | Medical instrument such as a neural implant, biopsy needle or an artificial landmark for implanting into human body, comprises a sample for permitting localization of the medical instruments into the human body, and transponder |
AU2007258592B2 (en) | 2006-06-06 | 2012-10-25 | Cook Incorporated | Stent with a crush-resistant zone |
EP2051673A2 (en) | 2006-06-23 | 2009-04-29 | Boston Scientific Limited | Bifurcated stent with twisted hinges |
US8202310B2 (en) * | 2006-07-14 | 2012-06-19 | Cordis Corporation | AAA repair device with aneurysm sac access port |
US8216267B2 (en) * | 2006-09-12 | 2012-07-10 | Boston Scientific Scimed, Inc. | Multilayer balloon for bifurcated stent delivery and methods of making and using the same |
US7951191B2 (en) | 2006-10-10 | 2011-05-31 | Boston Scientific Scimed, Inc. | Bifurcated stent with entire circumferential petal |
US8206429B2 (en) | 2006-11-02 | 2012-06-26 | Boston Scientific Scimed, Inc. | Adjustable bifurcation catheter incorporating electroactive polymer and methods of making and using the same |
JP5109194B2 (en) * | 2006-11-07 | 2012-12-26 | ウィリアム・エイ・クック・オーストラリア・プロプライエタリー・リミテッド | Stent graft |
US7842082B2 (en) | 2006-11-16 | 2010-11-30 | Boston Scientific Scimed, Inc. | Bifurcated stent |
US20080177377A1 (en) * | 2006-11-16 | 2008-07-24 | Boston Scientific Scimed, Inc. | Bifurcation Stent Design with Over Expansion Capability |
US8216298B2 (en) * | 2007-01-05 | 2012-07-10 | Medtronic Vascular, Inc. | Branch vessel graft method and delivery system |
US7959668B2 (en) | 2007-01-16 | 2011-06-14 | Boston Scientific Scimed, Inc. | Bifurcated stent |
US8118861B2 (en) * | 2007-03-28 | 2012-02-21 | Boston Scientific Scimed, Inc. | Bifurcation stent and balloon assemblies |
US8647376B2 (en) * | 2007-03-30 | 2014-02-11 | Boston Scientific Scimed, Inc. | Balloon fold design for deployment of bifurcated stent petal architecture |
US7632305B2 (en) * | 2007-07-06 | 2009-12-15 | Boston Scientific Scimed, Inc. | Biodegradable connectors |
US7637940B2 (en) * | 2007-07-06 | 2009-12-29 | Boston Scientific Scimed, Inc. | Stent with bioabsorbable membrane |
US20090030502A1 (en) * | 2007-07-26 | 2009-01-29 | Jichao Sun | Socket For Fenestrated Tubular Prosthesis |
US7959669B2 (en) | 2007-09-12 | 2011-06-14 | Boston Scientific Scimed, Inc. | Bifurcated stent with open ended side branch support |
US7833266B2 (en) | 2007-11-28 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment |
US8002816B2 (en) * | 2007-12-21 | 2011-08-23 | Cleveland Clinic Foundation | Prosthesis for implantation in aorta and method of using same |
US8277501B2 (en) | 2007-12-21 | 2012-10-02 | Boston Scientific Scimed, Inc. | Bi-stable bifurcated stent petal geometry |
US20090164001A1 (en) * | 2007-12-21 | 2009-06-25 | Biggs David P | Socket For Fenestrated Tubular Prosthesis |
JP5504173B2 (en) | 2007-12-31 | 2014-05-28 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Catheter assembly for vascular bifurcation treatment |
US20090259290A1 (en) * | 2008-04-14 | 2009-10-15 | Medtronic Vascular, Inc. | Fenestration Segment Stent-Graft and Fenestration Method |
US20090264985A1 (en) * | 2008-04-17 | 2009-10-22 | Medtronic Vascular, Inc. | Branch Vessel Suture Stent System and Method |
US20090287145A1 (en) * | 2008-05-15 | 2009-11-19 | Altura Interventional, Inc. | Devices and methods for treatment of abdominal aortic aneurysms |
US8932340B2 (en) | 2008-05-29 | 2015-01-13 | Boston Scientific Scimed, Inc. | Bifurcated stent and delivery system |
US8353943B2 (en) * | 2008-08-29 | 2013-01-15 | Cook Medical Technologies Llc | Variable weave graft with metal strand reinforcement for in situ fenestration |
US8052741B2 (en) * | 2009-03-23 | 2011-11-08 | Medtronic Vascular, Inc. | Branch vessel prosthesis with a roll-up sealing assembly |
US10137018B2 (en) * | 2009-04-23 | 2018-11-27 | Shaun L. W. Samuels | Endovascular router device and method |
EP2506797A4 (en) * | 2009-11-30 | 2016-10-19 | Biflow Medical Ltd | Method of implanting a stent graft and creating a fenestration therein |
ES2577853T3 (en) | 2009-12-01 | 2016-07-19 | Altura Medical, Inc. | Modular endograft devices |
DE102009060228B4 (en) * | 2009-12-23 | 2014-12-04 | Acandis Gmbh & Co. Kg | Medical devices |
US8771336B2 (en) | 2010-08-21 | 2014-07-08 | Cook Medical Technologies Llc | Endoluminal prosthesis comprising a valve replacement and at least one fenestration |
US8702786B2 (en) | 2010-08-21 | 2014-04-22 | Cook Medical Technologies Llc | Prosthesis having pivoting fenestration |
CA2748206C (en) | 2010-08-21 | 2015-06-23 | Blayne A. Roeder | Prosthesis having pivoting fenestration |
US8870939B2 (en) | 2010-08-21 | 2014-10-28 | Cook Medical Technologies Llc | Prosthesis having pivoting fenestration |
WO2012040240A1 (en) | 2010-09-20 | 2012-03-29 | Altura Medical, Inc. | Stent graft delivery systems and associated methods |
EP2635241B1 (en) * | 2010-11-02 | 2019-02-20 | Endologix, Inc. | Apparatus for placement of a graft or graft system |
US9566149B2 (en) | 2010-11-16 | 2017-02-14 | W. L. Gore & Associates, Inc. | Devices and methods for in situ fenestration of a stent-graft at the site of a branch vessel |
AU2011200858B1 (en) | 2011-02-28 | 2012-04-05 | Cook Medical Technologies Llc | Stent graft with valve arrangement |
US9168162B2 (en) | 2011-11-17 | 2015-10-27 | Elgco, Llc | Methods and apparatus for treating a type 2 endoleak from within an endoluminal stent |
US9811613B2 (en) | 2012-05-01 | 2017-11-07 | University Of Washington Through Its Center For Commercialization | Fenestration template for endovascular repair of aortic aneurysms |
WO2014026173A1 (en) | 2012-08-10 | 2014-02-13 | Cragg Andrew H | Stent delivery systems and associated methods |
AU2012258394B1 (en) * | 2012-11-27 | 2013-03-07 | Cook Medical Technologies Llc | Stent graft having a closeable fenestration |
US10265202B2 (en) | 2013-03-14 | 2019-04-23 | Cook Medical Technologies Llc | Prosthesis having an everting pivoting fenestration |
WO2014144809A1 (en) | 2013-03-15 | 2014-09-18 | Altura Medical, Inc. | Endograft device delivery systems and associated methods |
US9907680B2 (en) | 2015-04-10 | 2018-03-06 | Cook Medical Technologies Llc | Sliding fenestration |
EP3468505B1 (en) * | 2016-06-13 | 2021-02-24 | Aortica Corporation | Systems and devices for marking and/or reinforcing fenestrations in prosthetic implants |
EP3493766B1 (en) | 2016-08-02 | 2024-03-06 | Bolton Medical, Inc. | Assembly for coupling a prosthetic implant to a fenestrated body |
AR106485A1 (en) * | 2016-10-28 | 2018-01-17 | Barone Hector Daniel | PROSTHESIS FOR THE REPAIR OF A BLOOD GLASS AND IMPLANT METHOD |
WO2018156849A1 (en) | 2017-02-24 | 2018-08-30 | Bolton Medical, Inc. | Vascular prosthesis with fenestration ring and methods of use |
WO2018156851A1 (en) | 2017-02-24 | 2018-08-30 | Bolton Medical, Inc. | Vascular prosthesis with moveable fenestration |
EP3838220A1 (en) | 2017-02-24 | 2021-06-23 | Bolton Medical, Inc. | System to radially constrict a stent graft |
WO2018156848A1 (en) | 2017-02-24 | 2018-08-30 | Bolton Medical, Inc. | Vascular prosthesis with crimped adapter and methods of use |
WO2018156850A1 (en) | 2017-02-24 | 2018-08-30 | Bolton Medical, Inc. | Stent graft with fenestration lock |
WO2018156847A1 (en) | 2017-02-24 | 2018-08-30 | Bolton Medical, Inc. | Delivery system and method to radially constrict a stent graft |
CN111148484B (en) | 2017-09-25 | 2022-12-30 | 波尔顿医疗公司 | Systems, devices, and methods for coupling a prosthetic implant to an open window |
WO2019089071A1 (en) | 2017-10-31 | 2019-05-09 | Bolton Medical, Inc. | Distal torque component, delivery system and method of using same |
CN110236748B (en) * | 2019-05-30 | 2021-03-26 | 中国人民解放军陆军军医大学第一附属医院 | Exempt from to make accurate external windowing aortic support of order |
USD998779S1 (en) * | 2020-06-05 | 2023-09-12 | W. L. Gore & Associates, Inc. | Vent |
USD1004071S1 (en) * | 2020-11-30 | 2023-11-07 | W. L. Gore & Associates, Inc. | Vent |
WO2023091098A1 (en) * | 2021-11-22 | 2023-05-25 | Mehmet Hakan Akpinar | An implantable patch for vascular injuries with a blood perfusion system |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4482516A (en) * | 1982-09-10 | 1984-11-13 | W. L. Gore & Associates, Inc. | Process for producing a high strength porous polytetrafluoroethylene product having a coarse microstructure |
US4988356A (en) * | 1987-02-27 | 1991-01-29 | C. R. Bard, Inc. | Catheter and guidewire exchange system |
US5171222A (en) * | 1988-03-10 | 1992-12-15 | Scimed Life Systems, Inc. | Interlocking peel-away dilation catheter |
US5102403A (en) * | 1990-06-18 | 1992-04-07 | Eckhard Alt | Therapeutic medical instrument for insertion into body |
US5395335A (en) * | 1991-05-24 | 1995-03-07 | Jang; G. David | Universal mode vascular catheter system |
US5205822A (en) * | 1991-06-10 | 1993-04-27 | Cordis Corporation | Replaceable dilatation catheter |
US5135535A (en) * | 1991-06-11 | 1992-08-04 | Advanced Cardiovascular Systems, Inc. | Catheter system with catheter and guidewire exchange |
US5324269A (en) * | 1991-09-19 | 1994-06-28 | Baxter International Inc. | Fully exchangeable dual lumen over-the-wire dilatation catheter with rip seam |
US5389087A (en) * | 1991-09-19 | 1995-02-14 | Baxter International Inc. | Fully exchangeable over-the-wire catheter with rip seam and gated side port |
US5195978A (en) * | 1991-12-11 | 1993-03-23 | Baxter International Inc. | Rapid exchange over-the-wire catheter with breakaway feature |
US5683448A (en) * | 1992-02-21 | 1997-11-04 | Boston Scientific Technology, Inc. | Intraluminal stent and graft |
US5334147A (en) * | 1993-04-28 | 1994-08-02 | Cordis Corporation | Rapid exchange type dilatation catheter |
US5336184A (en) * | 1993-07-15 | 1994-08-09 | Teirstein Paul S | Rapid exchange catheter |
US5472425A (en) * | 1993-07-15 | 1995-12-05 | Teirstein; Paul S. | Rapid exchange catheter |
CA2169549C (en) * | 1993-08-18 | 2000-07-11 | James D. Lewis | A tubular intraluminal graft |
US5549663A (en) * | 1994-03-09 | 1996-08-27 | Cordis Corporation | Endoprosthesis having graft member and exposed welded end junctions, method and procedure |
US5489271A (en) * | 1994-03-29 | 1996-02-06 | Boston Scientific Corporation | Convertible catheter |
US5476589A (en) * | 1995-03-10 | 1995-12-19 | W. L. Gore & Associates, Inc. | Porpous PTFE film and a manufacturing method therefor |
US6579314B1 (en) * | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
DE69635659T2 (en) * | 1995-06-01 | 2006-07-06 | Meadox Medicals, Inc. | IMPLANTABLE INTRALUMINARY PROSTHESIS |
EP1011889B1 (en) * | 1996-01-30 | 2002-10-30 | Medtronic, Inc. | Articles for and methods of making stents |
US6432127B1 (en) * | 1996-10-11 | 2002-08-13 | Transvascular, Inc. | Devices for forming and/or maintaining connections between adjacent anatomical conduits |
US6835203B1 (en) * | 1996-11-04 | 2004-12-28 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US5807355A (en) * | 1996-12-09 | 1998-09-15 | Advanced Cardiovascular Systems, Inc. | Catheter with rapid exchange and OTW operative modes |
KR19990010304A (en) * | 1997-07-16 | 1999-02-18 | 장양수 | Blood vessel stent |
US5984955A (en) * | 1997-09-11 | 1999-11-16 | Wisselink; Willem | System and method for endoluminal grafting of bifurcated or branched vessels |
EP1032328A1 (en) * | 1997-11-25 | 2000-09-06 | Triad Vascular Systems Inc. | Layered endovascular graft |
AUPP083597A0 (en) * | 1997-12-10 | 1998-01-08 | William A Cook Australia Pty Ltd | Endoluminal aortic stents |
US6395018B1 (en) * | 1998-02-09 | 2002-05-28 | Wilfrido R. Castaneda | Endovascular graft and process for bridging a defect in a main vessel near one of more branch vessels |
US6261273B1 (en) * | 1998-05-07 | 2001-07-17 | Carlos E. Ruiz | Access system for branched vessels amd methods of use |
US6095990A (en) * | 1998-08-31 | 2000-08-01 | Parodi; Juan Carlos | Guiding device and method for inserting and advancing catheters and guidewires into a vessel of a patient in endovascular treatments |
US6071307A (en) * | 1998-09-30 | 2000-06-06 | Baxter International Inc. | Endoluminal grafts having continuously curvilinear wireforms |
US6398803B1 (en) * | 1999-02-02 | 2002-06-04 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Partial encapsulation of stents |
US6273911B1 (en) * | 1999-04-22 | 2001-08-14 | Advanced Cardiovascular Systems, Inc. | Variable strength stent |
BR9901540C1 (en) * | 1999-05-17 | 2001-12-18 | Fundacao Zerbini | Device for unblocking atherosclerotic lesions that include the origin of lateral branches or located in bifurcations of the coronary circulation, and the respective intervention process for placing the referred device |
US6673103B1 (en) * | 1999-05-20 | 2004-01-06 | Scimed Life Systems, Inc. | Mesh and stent for increased flexibility |
US6361555B1 (en) * | 1999-12-15 | 2002-03-26 | Advanced Cardiovascular Systems, Inc. | Stent and stent delivery assembly and method of use |
US6299595B1 (en) * | 1999-12-17 | 2001-10-09 | Advanced Cardiovascular Systems, Inc. | Catheters having rapid-exchange and over-the-wire operating modes |
US6245100B1 (en) * | 2000-02-01 | 2001-06-12 | Cordis Corporation | Method for making a self-expanding stent-graft |
US20020193872A1 (en) * | 2001-06-18 | 2002-12-19 | Trout Hugh H. | Prosthetic graft assembly and method of use |
US20030130720A1 (en) * | 2002-01-08 | 2003-07-10 | Depalma Donald F. | Modular aneurysm repair system |
US20040054403A1 (en) * | 2002-09-18 | 2004-03-18 | Israel Henry M | Angular orientation of a stent |
-
2002
- 2002-09-20 US US10/251,031 patent/US20040059406A1/en not_active Abandoned
-
2003
- 2003-09-16 EP EP03754655A patent/EP1539037B1/en not_active Expired - Lifetime
- 2003-09-16 AU AU2003272473A patent/AU2003272473B2/en not_active Expired
- 2003-09-16 JP JP2004537900A patent/JP4571498B2/en not_active Expired - Lifetime
- 2003-09-16 CA CA002498176A patent/CA2498176C/en not_active Expired - Lifetime
- 2003-09-16 AT AT03754655T patent/ATE311834T1/en not_active IP Right Cessation
- 2003-09-16 WO PCT/US2003/029200 patent/WO2004026181A1/en active IP Right Grant
- 2003-09-16 DE DE60302674T patent/DE60302674T2/en not_active Expired - Lifetime
-
2013
- 2013-07-31 US US13/955,899 patent/US9694108B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20040059406A1 (en) | 2004-03-25 |
WO2004026181A1 (en) | 2004-04-01 |
US20130317601A1 (en) | 2013-11-28 |
AU2003272473B2 (en) | 2006-12-07 |
EP1539037B1 (en) | 2005-12-07 |
DE60302674T2 (en) | 2006-08-31 |
CA2498176A1 (en) | 2004-04-01 |
JP2006500107A (en) | 2006-01-05 |
EP1539037A1 (en) | 2005-06-15 |
DE60302674D1 (en) | 2006-01-12 |
ATE311834T1 (en) | 2005-12-15 |
US9694108B2 (en) | 2017-07-04 |
JP4571498B2 (en) | 2010-10-27 |
AU2003272473A1 (en) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2498176C (en) | Medical device amenable to fenestration | |
US10682222B2 (en) | Modular vascular graft for low profile percutaneous delivery | |
US20200330214A1 (en) | Apparatus and methods for endoluminal graft placement | |
US11065097B2 (en) | Advanced kink-resistant stent graft | |
EP0971645B1 (en) | Coiled sheet graft for single and bifurcated lumens and methods of making | |
EP1734899B1 (en) | Encapsulated stent-graft with graft to graft attachment | |
US20140005764A1 (en) | Sealing mechanism for expandable vascular device | |
JP2007536951A (en) | Intraluminal artificial blood vessel with neointimal inhibitory polymer sleeve | |
KR20160140688A (en) | Stent assembly for thoracoabdominal bifurcated aneurysm repair | |
JP2002191703A (en) | Stent implant having improved means for attaching stent to implant | |
JP5318604B2 (en) | Method and apparatus for attaching a stent structure to an AAA graft material | |
KR20020012574A (en) | Stent-graft with increased flexibility | |
JP2020533080A (en) | Intraluminal artificial vascular system | |
US20220257363A1 (en) | Bifurcated stent grafts, stents, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20230918 |